Dr. Joseph Goldstein and others studied extensive family trees of cardiac victims in an effort to segregate genetically determined events from uninherited events. They then studied the type of lipids involved for the genetically determined group. This resulted in the “delineat(ion)” of “five distinct lipid disorders,” of which two will be key to understanding today’s patient swap. One lipid was cholesterol (LDL) and the other, triglyceride (TG). Those with high LDL and relatively normal TG were “the disorder easiest to detect, familial hypercholesterolemia.” On the other hand, those with a combination ofhigh LDL and high TG, were called, “familial combined hyperlipidemia.” In the future, Dr. Goldstein will team up with Dr. Michael Brown, and they will win the Nobel Prize for the discovery of the precise cause of FH, the LDL Receptor mutation (LDLR). The identification procedure for FH moves away from relying on weaker forms of circumstantial evidence to the promise of decisive, genetic matching: precision medicine is here. FCH however will not yield the same clarity in the future. Its cause remains elusive.